---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-016160"
form_type: "8-K"
ticker: "FEMY"
cik: "0001339005"
company_name: "FEMASYS INC"
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T05:53:30.625253+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Femasys FY23 net loss $14.25M, sales down 11%; FemaSeed FDA clearance and positive trial data

## Summary
- Net loss $14.25M ($0.93/share) vs $11.39M ($0.96/share) in FY22; sales $1.07M (-11% YoY).
- FDA cleared FemaSeed for infertility; pivotal trial showed 24% pregnancy rate in severe male factor cohort.
- Cash $21.7M expected to fund operations into 2H 2025; convertible notes of $4.26M issued.
- Appointed Richard Spector as CCO and James Liu as CMO.
- FemBloc permanent birth control trial enrollment initiated.

## SEC filing metadata
- accession: 0001140361-24-016160
- form_type: 8-K
- ticker: FEMY
- cik: 0001339005
- company_name: FEMASYS INC
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339005/000114036124016160/0001140361-24-016160-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339005/000114036124016160/ef20025488_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-016160
- JSON: https://secwatch.observer/filing/0001140361-24-016160.json
- Plain text: https://secwatch.observer/filing/0001140361-24-016160.txt

## Key facts
- Earnings Releases
  FEMASYS INC reported year ended December 31, 2023 results: net income Net loss was $14,247,124 or $0.93 per basic and diluted share attributable to common stockholders.
  - Period: year ended December 31, 2023
  - Net income: Net loss was $14,247,124 or $0.93 per basic and diluted share attributable to common stockholders
  - Result: reported results
  source text: Net loss was $14,247,124 or $0.93 per basic and diluted share attributable to common stockholders, for the year ended December 31, 2023, compared to net loss of $11,394,170, or $0.96 per basic and diluted share attributable to common stockholders, for the year ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1339005/000114036124016160/0001140361-24-016160-index.htm
- Earnings Releases
  FEMASYS INC reported year ended December 31, 2022 results: net income net loss of $11,394,170, or $0.96 per basic and diluted share attributable to common stockholders.
  - Period: year ended December 31, 2022
  - Net income: net loss of $11,394,170, or $0.96 per basic and diluted share attributable to common stockholders
  - Result: reported results
  source text: Net loss was $14,247,124 or $0.93 per basic and diluted share attributable to common stockholders, for the year ended December 31, 2023, compared to net loss of $11,394,170, or $0.96 per basic and diluted share attributable to common stockholders, for the year ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1339005/000114036124016160/0001140361-24-016160-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.